| 摘要 |
The following are claimed: (1) use of compounds that block neuronal potassium channels of the Kv1.1, Kv1.2 and optionally KV1.3 type to prepare therapeutics for treating human or animal neurological disorders, optionally of immune origin, in which nerve signal transmission is blocked; (2) kaliotoxin 3 having the amino acid sequence (I); (3) peptides of formula (II): Val Gly Ile Pro Val Ser Cys Lys His Ser Gly Gln Cys Ile Lys Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys Cys Asp Cys Thr Pro Lys (I) Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Cys Xaa9 Xaa10 Ser Xaa12 Gln Cys Xaa15 Lys Xaa17 Cys Lys Asp Ala Xaa22 Gly Xaa24 Arg Phe Gly Lys Cys Xaa31 Asn Xaa33 Lys Cys Xaa36 Cys Xaa38 Xaa39 Xaa40 (III) Xaa1-Xaa7, Xaa9, Xaa10, Xaa12, Xaa15, Xaa17, Xaa22, Xaa24, Xaa31, Xaa33, Xaa36 and Xaa38-Xaa40 are any natural or unnatural amino acids, provided that: Xaa12 = aminobutyric acid (Abu) or Lys, and/or Xaa17 = Abu or Val, and/or Xaa22 = Phe or is absent, and/or Xaa24 and Xaa 31 = Met or Nle.
|
